Variations in the management of the axilla in screendetected Ductal Carcinoma In Situ: Evidence from the UK NHS breast screening programme audit of screen detected DCIS

European Journal of Surgical Oncology

Volumn 41, Issue 1, 2015, Pages 86-93

  Nicholson, S ^a   Hanby, A ^a   Clements, K ^a   Kearins, O ^a   Lawrence, G ^a   Dodwell, D ^a   Bishop, H ^a   Thompson, A ^a   Thompson, Alastair ^b,c   Ball, Graham ^b   Clements, Karen ^d   Dobson, Hilary ^e   Dodwell, David ^f   Evans, Andrew ^g   Hanby, Andrew ^h   Kearins, Olive ⁱ   Lawrence, Gill ^e   Maxwell, Anthony ^e   Nicholson, Stewart ^j   Pinder, Sarah ^k   Thomas, Jeremy ^l   Wallis, Matthew ^m   Wheaton, Margot ⁿ   Bishop, Hugh ⁿ   more..

^a West Midlands Breast and Cervical Screening QA Reference Centre   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f West of Scotland Breast Screening Service   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h NINEWELLS HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j ROYAL BOLTON HOSPITAL   (United Kingdom)

^k ROYAL VICTORIA INFIRMARY   (United Kingdom)

^l GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^m WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁿ Western General Hospital ^*

more..

Author keywords

Axillary surgery; Breast screening; DCIS; Extent of surgery

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER SCREENING; CANCER SIZE; CANCER STAGING; FEMALE; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL AUDIT; NATIONAL HEALTH SERVICE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; ULTRASOUND; UNITED KINGDOM; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DIAGNOSIS; FINE NEEDLE ASPIRATION BIOPSY; LYMPH NODE; LYMPH NODE DISSECTION; MAMMOGRAPHY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SEGMENTAL MASTECTOMY;

AXILLA; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; FEMALE; GREAT BRITAIN; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MAMMOGRAPHY; MASTECTOMY; MASTECTOMY, SEGMENTAL; MEDICAL AUDIT; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; STATE MEDICINE;

EID: 84925024869     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.09.003     Document Type: Article

References (30)

1. NHS Breast Screening Programme. http://www.cancerscreening.nhs.uk/breastscreen.
2. American Cancer Society. Cancer Facts and figures 2006. http://www.cancer.org.downloads/STT/CAFF2006PW.
3. Houssani N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of core-needle biopsy. Cancer 2007;109:487-95.
4. Mokbel K, Cutuli B. Heterogenicity of ductal carcinoma in situ and its effects on management. Lancet Oncol 2006;7:756-65.
5. Lee CH, Carter D, Philpotts LE, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 2000;217:466-70.
6. Hoorntz LE, Schipper ME, Peeters PH, Bellot F, Storm RK, Borel Rinkers IH. The finding of invasive cancer after a preoperative diagnosis of ductal Carcinoma in situ: causes of ductal carcinoma in situ underestimates with Stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003;10:748-53.
7. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD. Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J Clin Pathol 2006;59: 740-3.
8. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443-8.
9. Silverstein MJ, Gierson ED, Colburn WJ, Rosser RJ, Waismann JR, Gamagami P. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991;172:211-4.
10. Malby H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg 2006;192:455-7.
11. Mansel RE, Fallowfield L, Kissin M, et al. Randomised multicenter trial of sentinel lymph node biopsy versus standard Axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
12. Veronesi V, Paganelli G, Galimberti V, et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
13. Giuliano AE, Jones RC, Brennan M, Statman RR. Sentinel lymphadenopathy in breast cancer. J Clin Oncol 1997;15:2345-50.
14. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000;7:15-20.
15. Moran CJ, Kell MR, Kerrin MJ. The role of sentinel lymph node biopsy in ductal carcinoma in situ. EJSO 2005;31:1105-11.
16. NICE Clinical Guidelines (CG80) e Breast cancer (early and locally advanced): Diagnosis and Treatment. www.nice.org.uk/CG80.
17. Surgical guidelines for the management of breast cancer. Association of breast surgery at BASO 2009. EJSO 2009;35(supplement):S1-22.
18. Bland M, Altman DG. Statistics Notes: the odds ratio. BMJ 2000;320: 1468.
19. Keshtgar M, Aresti N, MacNeill F. Establishing axillary sentinel node biopsy (SLNB) for early breast cancer in the United Kingdom. A survey of the national training programme. EJSO 2010;36:393-8.
20. Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg 2008;95:547-54.
21. Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol 2007;14: 2202-8.
22. Cox CE, Ngeryen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67:513-9.
23. Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal Carcinoma in situ. Am J Surg 2005;190:563-6.
24. Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastases in ductal carcinoma in situ: A clinicopathological study with long term follow up. Cancer 2003;98: 2105-13.
25. Jakub JW, Cox CE, Pippas AW, Gardner M, Pendas S, Reintgen DS. Controversial topics in breast cancer lymphatic mapping. Semin Oncol 2004;31:324-32.
26. NHSBSP, ABS. An audit of screen-detected breast cancers for the year of screening April 2009 to March 2010 May 2011. NHSBSP.
27. Fortunato L, Santoni M, Drago S, et al. Sentinel node biopsy in women with pT1a or "microinvasive" breast cancer. Breast 2008;17: 395-400.
28. Soumian S, Verghese ET, Booth M, et al. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed low risk DCIS trial. EJSO 2013;39:1337-40.
29. Van der Ploeg IMC, Nieweg OE, van Rijk MC, Valdesolmos RA, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast Cancer patients: A systematic review and metanalysis of the literature. EJSO 2008;34:1277-84.
30. Pernas S, Gil M, Benitez A, et al. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: A prospective analysis of axillary or distal recurrence. Ann Surg Oncol 2010;17:772-7.